SHP2/CDK4-IN-1, identified by its CAS number 2924036-87-1, is a small molecule inhibitor that targets the SHP2 protein and cyclin-dependent kinase 4 (CDK4). This compound is primarily investigated for its potential therapeutic applications in cancer treatment, particularly in tumors that exhibit aberrant signaling through the SHP2 pathway or reliance on CDK4 for cell cycle progression. The characteristics of SHP2/CDK4-IN-1 include its ability to selectively inhibit these targets, thereby disrupting oncogenic signaling pathways and potentially leading to reduced tumor growth. The compound is typically characterized by its molecular structure, which includes specific functional groups that confer its inhibitory activity. Additionally, it may exhibit properties such as solubility in various solvents, stability under physiological conditions, and a defined pharmacokinetic profile that influences its bioavailability and efficacy in vivo. Ongoing research aims to elucidate its mechanism of action, optimize its pharmacological properties, and evaluate its safety and effectiveness in clinical settings.

SHP2/CDK4-IN-1

2924036-87-1: SHP2/CDK4-IN-1, identified by its CAS number 2924036-87-1, is a small molecule inhibitor that targets the SHP2 protein and cyclin-dependent kinase 4 (CDK4). This compound is primarily investigated for its potential therapeutic applications in cancer treatment, particularly in tumors that exhibit aberrant signaling through the SHP2 pathway or reliance on CDK4 for cell cycle progression. The characteristics of SHP2/CDK4-IN-1 include its ability to selectively inhibit these targets, thereby disrupting oncogenic signaling pathways and potentially leading to reduced tumor growth. The compound is typically characterized by its molecular structure, which includes specific functional groups that confer its inhibitory activity. Additionally, it may exhibit properties such as solubility in various solvents, stability under physiological conditions, and a defined pharmacokinetic profile that influences its bioavailability and efficacy in vivo. Ongoing research aims to elucidate its mechanism of action, optimize its pharmacological properties, and evaluate its safety and effectiveness in clinical settings.

SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.

CAS 2924036-87-1

SHP2/CDK4-IN-1

SHP2/CDK4-IN-1

Ref: TM-T72836